Oligonucleotide Therapy Market Report 2026

Oligonucleotide Therapy Market Overview

• Oligonucleotide Therapy market size has reached to $6.2 billion in 2025 • Expected to grow to $10.87 billion in 2030 at a compound annual growth rate (CAGR) of 12% • Growth Driver: Government-Led Healthcare Research And Development Initiatives A Boost For Oligonucleotide Therapy • Market Trend: Elevating Pediatric Care Innovative Therapies In The Oligonucleotide Therapy Market • North America was the largest region in 2025.

What Is Covered Under Oligonucleotide Therapy Market?

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction) The main types of oligonucleotide therapy are antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are synthetic DNA oligomers that hybridize to a target RNA in a sequence-specific manner. They’ve been used to successfully limit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. It is used in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and others, and is implemented in hospitals, and research institutes.

What Is The Oligonucleotide Therapy Market Growth Forecast?

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of personalized medicine, integration of ai in drug discovery, growth of precision medicine initiatives, development of next-gen delivery platforms, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include targeted gene regulation, rna interference-based therapeutics, personalized medicine development, advanced drug delivery systems, nucleic acid-based diagnostics.

Global Oligonucleotide Therapy Market Segmentation

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types 2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User 3) By End User: Hospitals, Research Institutes Subsegments: 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides 2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers 3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

What Is The Driver Of The Oligonucleotide Therapy Market?

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the oligonucleotide therapy market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Several government authorities are initiating various healthcare initiatives to support various aspects including oligonucleotide therapy. For instance, in April 2025, according to the American Medical Association, a US-based Professional organizations, in 2023, U.S. health spending climbed 7.5% to $4.9 trillion, or $14,570 per capita, outpacing the 4.6% increase seen in 2022. Therefore, the Government initiatives for research and development in healthcare are driving the growth of the oligonucleotide therapy industry.

Key Players In The Global Oligonucleotide Therapy Market

Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.

Global Oligonucleotide Therapy Market Trends and Insights

Major companies operating in oligonucleotide therapy market are focusing on developing advanced treatments, such as gene therapies, to address the root cause of genetic diseases, improve patient outcomes, and reduce long-term treatment burden. Gene therapies refer to advanced medical treatments designed to introduce a functional gene into a patient's cells to compensate for a non-functional or mutated one. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received Food and Drug administration (FDA) approval for ELEVIDYS. It is a first-of-its-kind gene therapy for ambulatory pediatric patients with Duchenne muscular dystrophy (DMD). It is a single-dose treatment designed to deliver a gene that codes for a shortened functional form of dystrophin to muscle cells, aiming to halt or reverse the progression of the disease.

What Are Latest Mergers And Acquisitions In The Oligonucleotide Therapy Market?

In April 2025, AlphaRose Therapeutics, a US-based biopharmaceutical company, acquired Alpha Anomeric SA, for an undisclosed amount. With this acquisition, AlphaRose Therapeutics aims to strengthen its oligonucleotide therapeutics portfolio, accelerate innovation in gene-targeted therapies, expand its R&D capabilities, and enhance its competitive position in the global nucleic acid therapeutics market. Alpha Anomeric SA is a France-based company that offers a oligonucleotide therapy.

Regional Insights

North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oligonucleotide Therapy Market?

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oligonucleotide Therapy Market Report 2026?

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.